Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

64.91
+0.46000.71%
Volume:1.18M
Turnover:76.31M
Market Cap:12.55B
PE:171.27
High:65.66
Open:64.48
Low:64.46
Close:64.45
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.77
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.98
PE(LYR):36.06

Loading ...

Press Release: BioMarin Announces Close of the Alesta Therapeutics Acquisition

Dow Jones
·
Sep 01

BioMarin price target raised to $90 from $88 at Piper Sandler

TIPRANKS
·
Sep 01

BioMarin Pharmaceutical (BMRN) Receives a Buy from Wells Fargo

TIPRANKS
·
Sep 01

Biomarin Pharmaceutical Inc. : H.c. Wainwright Raises Target Price to $60 from $59

THOMSON REUTERS
·
Aug 31

U.s. Stocks on the Move-Pinterest, Intel, Slb

Reuters
·
Aug 31

Movement Alert|Biomarin Pharmaceutical Rises 5.08% in Pre-Market Trading, Reaches Global Patent Settlement With Ascendis Pharma Securing Up to 20% Royalty on Yuviwel Sales

Market Focus
·
Aug 31

Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties

Reuters
·
Aug 31

Intel, ServiceNow, Chevron, Strategy, and More Stocks That Explain Today's Market

Dow Jones
·
Aug 31

BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

TIPRANKS
·
Aug 31

Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma

THOMSON REUTERS
·
Aug 31

BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel

MT Newswires Live
·
Aug 31

Biomarin Pharmaceutical - Settlement Includes License for Biomarin Patents Relating to Yuviwel for All Indications

THOMSON REUTERS
·
Aug 31

Biomarin Pharmaceutical - Ascendis to Pay Biomarin 20% Royalty on Yuviwel U.S. Sales, 18% in EU, Brazil, South Korea Until May 2030

THOMSON REUTERS
·
Aug 31

Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries

THOMSON REUTERS
·
Aug 31

BioMarin (BMRN) Stock Looks To Trade At A Discount To Fair Value

Simply Wall St.
·
Aug 31

U.S. Stocks on the MOVE-BioMarin Pharmaceutical, Home Depot, Klarna Group

Reuters
·
Aug 18

BioMarin Pharmaceutical's Alesta Deal Strengthens Long-Term Growth Outlook, Wedbush Says

MT Newswires Live
·
Aug 18

Biomarin Pharmaceutical Inc. : H.c. Wainwright Cuts Target Price to $59 from $60

THOMSON REUTERS
·
Aug 18

BioMarin Adds Potential Bone-Disease Treatment to Portfolio

Dow Jones
·
Aug 18

BioMarin Agrees to Buy Alesta Therapeutics for USD 275 Million Upfront

Reuters
·
Aug 18